» Articles » PMID: 2981341

Protection of Mice from Wild-type Sendai Virus Infection by a Trypsin-resistant Mutant, TR-2

Overview
Journal J Virol
Date 1985 Jan 1
PMID 2981341
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

A trypsin-resistant mutant of Sendai virus, TR-2, which could be activated by chymotrypsin but not by trypsin or the protease present in mouse lung, was inoculated intranasally into mice after being activated in vitro. TR-2 hardly brought about clinical illness or lung lesions in mice; the protease present in the lung could not activate the progeny virus, and the infection terminated after one-step replication. Nevertheless, the immunoglobulin A antibody against wild-type Sendai virus was produced in the respiratory tracts as well as the serum immunoglobulin G antibody, and the mice were protected from the challenge of the wild-type Sendai virus. On the basis of these results, TR-2 may provide a new model of live vaccine for paramyxoviruses; its availability as a live vaccine is also discussed.

Citing Articles

First Isolation and Characteristics of Bovine Parainfluenza Virus Type 3 from Yaks.

Ren Y, Chen X, Tang C, Yue H Pathogens. 2022; 11(9).

PMID: 36145395 PMC: 9503188. DOI: 10.3390/pathogens11090962.


Wheat germ cell-free system-based production of hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3 for generation and characterization of monoclonal antibody.

Matsunaga S, Kawakami S, Matsuo I, Okayama A, Tsukagoshi H, Kudoh A Front Microbiol. 2014; 5:208.

PMID: 24860558 PMC: 4026691. DOI: 10.3389/fmicb.2014.00208.


Parainfluenza viruses.

Henrickson K Clin Microbiol Rev. 2003; 16(2):242-64.

PMID: 12692097 PMC: 153148. DOI: 10.1128/CMR.16.2.242-264.2003.


Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses.

Takao S, Kiyotani K, Sakaguchi T, Fujii Y, Seno M, Yoshida T J Virol. 1997; 71(1):832-8.

PMID: 8985426 PMC: 191127. DOI: 10.1128/JVI.71.1.832-838.1997.


A protease activation mutant, MVCES1, as a safe and potent live vaccine derived from currently prevailing Sendai virus.

Wang X, Itoh M, Hotta H, Homma M J Virol. 1994; 68(5):3369-73.

PMID: 8151795 PMC: 236828. DOI: 10.1128/JVI.68.5.3369-3373.1994.


References
1.
Homma M, TAMAGAWA S . Restoration of the fusion activity of L cell-borne Sendai virus by trypsin. J Gen Virol. 1973; 19(3):423-6. DOI: 10.1099/0022-1317-19-3-423. View

2.
Parker J, Whiteman M, Richter C . Susceptibility of inbred and outbred mouse strains to Sendai virus and prevalence of infection in laboratory rodents. Infect Immun. 1978; 19(1):123-30. PMC: 414057. DOI: 10.1128/iai.19.1.123-130.1978. View

3.
Ishida N, Homma M . Host-controlled variation observed with Sendai virus grown in mouse fibroblast (L) cells. Virology. 1961; 14:486-8. DOI: 10.1016/0042-6822(61)90342-7. View

4.
SILVER S, Scheid A, Choppin P . Loss on serial passage of rhesus monkey kidney cells of proteolytic activity required for Sendai virus activation. Infect Immun. 1978; 20(1):235-41. PMC: 421577. DOI: 10.1128/iai.20.1.235-241.1978. View

5.
Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View